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E-mail address: pascal.pomies@crbm.cnrs.fr (P. PoVarious expression studies have shown a preferential muscle expression of the mouse Fem1a gene,
but no data is available on the subcellular localization of the corresponding protein. Here, using a
speciﬁc antibody, we show that Fem1a is expressed preferentially in cardiac muscle, brain and liver.
Moreover, using immunoﬂuorescence and electron microscopy, as well as biochemical assays, we
demonstrate that Fem1a is localized within mitochondria of C2C12 myoblasts and cardiac muscle
cells. Finally, we show that the expression of Fem1a, which is a cellular partner of the EP4 receptor
for prostaglandin E2, is increased in mouse hearts after myocardial infarction.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
In the nematode Caenorhabditis elegans, fem-1, fem-2 and fem-3,
members of the fem gene family, are necessary for male fate deter-
mination and are speciﬁcally required for somatic and germline
sexual differentiation [1]. More recently, murine Fem1a and human
FEM1A genes, the ortholog genes of the Caenorhabditis elegans gene
fem-1, have been identiﬁed [2,3]. Human FEM1A shares 89% of its
amino acids with mouse Fem1a and 33% with the nematode
FEM-1.
In recent studies, human FEM1A has been proposed as a candi-
date gene for polycystic ovary syndrome (PCOS), an endocrine dis-
order affecting women. Indeed, the FEM1A gene maps to
chromosome 19p13.3, a locus that has been shown to be associated
with PCOS. Moreover, an heterozygous germline mutation in the
FEM1A gene has been found in a patient with PCOS [4], and genetic
studies have revealed that FEM1A single nucleotide polymor-
phisms were associated with an increased likelihood of PCOS [5].
It has also been shown that the mouse Fem1a gene, as well as its
human ortholog FEM1A, are preferentially expressed in cardiac and
skeletal muscles [2,3,6]. In the mouse C2C12 cell line, a cell culturechemical Societies. Published by E
R5237, 1919 route de Mende,
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miès).model routinely used for the study of skeletal muscle differentia-
tion, the expression of Fem1amRNA increases progressively during
the differentiation process [2]. Furthermore, Fem1a expression is
down-regulated in rhabdomyosarcoma cells suggesting that the
Fem1a gene may be involved in muscle differentiation or be at least
a marker of abnormal differentiation in rhabdomyosarcoma [2].
Several years ago, a set of 14 transcripts preferentially or specif-
ically expressed in human muscle has been identiﬁed based on
cDNA array hybridization [6]. One of these gene transcripts, named
GENX-3587, has been further characterized: its gene localization
has been assigned to chromosome 19p13.3, while its preferential
muscle expression has been conﬁrmed by Northern blot analysis
[6]. Sequence similarity searches have revealed that the human
GENX-3587 sequence corresponds to human FEM1A. But to date,
while various gene expression studies have been performed, no
protein expression data are available for the mouse protein Fem1a
or the human protein FEM1A. Therefore, we have generated a spe-
ciﬁc polyclonal antibody and have shown that Fem1a is preferen-
tially expressed in organs enriched in mitochondria such as
cardiac muscle, brain and liver. Furthermore, using immunoﬂuo-
rescence and electron microscopy as well as biochemical assays,
we demonstrated for the ﬁrst time that Fem1a is a mitochondrial
protein. Interestingly, we have also observed that Fem1a expres-
sion is up-regulated in hearts from mice subjected to ischemia–
reperfusion injury.lsevier B.V. All rights reserved.
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2.1. Cell culture
C2C12, HeLa and rhabdomyosarcoma RD and Rh28 cell lines
were routinely cultured in complete Dulbecco’s Modiﬁed Eagle’s
Medium (Lonza, Switzerland) supplemented with 10% fetal bovine
serum (FBS; Invitrogen, Carlsbad, CA). To induce differentiation,
C2C12 cells were cultured for up to 7 days using the same medium
with FBS replaced by 2% horse serum (Biochrom-Seromed, France).
2.2. SDS–PAGE and Western immunoblotting
Mouse organs were frozen in liquid nitrogen, blended in a pot-
ter and resuspended in Laemmli buffer at a concentration of
100 mg/ml. Bacteria and C2C12 cells were centrifuged and then
resuspended in Laemmli buffer. Samples were boiled and an equal
amount of proteins were separated by SDS-polyacrylamide gels
and transferred to nitrocellulose or PVDF membranes. Enhanced
chemiluminescence was used to detect proteins.
2.3. P3587 antibody production
The human FEM1A cDNA was cloned into the pQE-TriSystem
vector (QIAGEN, Hilden, Germany) allowing the expression of
FEM1A coupled to a 8-histidine tag. The protein was expressed in
bacteria and then puriﬁed using a Ni–NTA agarose column (QIA-
GEN) according to the manufacturer instructions. The puriﬁed pro-
tein was then used to immunize a rabbit for production of the
P3587 antibody.
2.4. Lambda phosphatase assay
C2C12 myoblasts and 2- and 6-day differentiating myotubes
were lysed on ice for 15 min in PBS/2% Triton X-100/protease
inhibitors. Lysates were centrifuged for 2 min at 1000 rpm. 0,
300, 600 or 1800 units of Lambda phosphatase (BioLabs, Ipswich,
MA) were added to the supernatant for 1 h at 30 C. Laemmli buffer
was added to stop the reaction and the proteins were separated on
SDS–PAGE and subjected to Western immunoblotting.
2.5. Immunoﬂuorescence microscopy
Cells grown in 60-mm culture dishes were ﬁxed with PBS/3.7%
formaldehyde for 15 min and then permeabilized for 5 min in PBS/
0.1% Triton X-100. 10 lm-cryosat muscle sections were saturated
in PBS/1% BSA for 15 min at 37 C. For immunostaining of cells and
muscle sections, we used the polyclonal P3587 antibody followed
byaFITC-conjugatedgoatanti-rabbitantibody (Jackson ImmunoRe-
search Laboratories, Inc., West Grove, PA), and an anti-cytochrome c
monoclonal antibody (BDPharMingen, Franklin Lakes,NJ) or ananti-
a-actinin 2monoclonal antibody (Sigma–Aldrich, St. Louis, MO) fol-
lowedby a Texas red-conjugated goat anti-mouse antibody (Jackson
Immuno Research Laboratories, Inc.).
Images were captured with a MicroMax 1300 CCD camera
(charge-coupled-device camera; RS-Princeton Instruments, Tren-
ton, NJ) driven by MetaMorph software (v.4.11; Universal Imaging
Corp., Westchester, PA) on a TEM Zeiss EM10 CR microscope (Carl
Zeiss, Germany).
2.6. Subcellular fractionation
Isolation of mitochondria from C2C12myoblasts was performed
as described previously for cell lines [7]. Cells were harvested in
PBS, centrifuged, and the cell pellet was resuspended in ice-coldmitochondrial isolation buffer (210 mM mannitol, 70 mM sucrose,
1 mM EDTA, 10 mM HEPES pH 7.5 with protease inhibitors). Cells
were then blended with a Dounce homogeniser. Nuclei and unbro-
ken cells were removed by centrifugation for 10 min at 800g at
4 C. Mitochondria were then pelleted and isolated by further cen-
trifugation for 15 min at 15 000g at 4 C. Equal protein amount of
cytosolic and mitochondrial fractions were separated by SDS–PAGE
and subjected to Western immunobloting.
Isolation of mitochondria from mouse hearts was performed as
described previously for rat organs [8]. Freshly taken hearts were
washed 3 times in washing buffer (10 mM Tris pH 7.4, 0.25 M su-
crose), cut into small pieces, and washed again 3 times in washing
buffer. The heart samples were then placed in buffer 1 (10 mM
HEPES pH 7.5, 0.25 M sucrose) and were blended using a Dounce
homogeniser. Nuclei and unbroken cells were removed by centrifu-
gation at 1000g for 10 min at 4 C. The resulting supernatant was
centrifuged for 15 min at 16 000g at 4 C to isolate mitochondria
from the cytosolic fraction. Mitochondria were then resuspended
inbuffer 2 (10 mMTrispH7.5, 0.25 Msucrose, 1 mMEDTA, 0.1%eth-
anol), and centrifuged for 15 min at 16 000g at 4 C. Isolatedmito-
chondria were ﬁnally resuspended in buffer 2.
2.7. Electron microscopy
C2C12 myoblasts were ﬁxed for 48 h at 4 C in phosphate buffer
0.1 M/4% paraformaldehyde and then washed in PBS/10% FBS. Cells
were then included in PBS/10% FBS/7.5% gelatin. The cell pellet was
cut in small cubes that were incubated in polyvinylpyrrolidone/
2.3 M sucrose over night, and then frozen in liquid nitrogen. Ul-
tra-thin sections were performed using an UCT-EMFCS Leica
microtome (Leica, Germany) and a diamond knife at 45 (Diatome,
Switzerland). Sections were harvested following the Tokuyasu
method’s [9] on nickel grid and then incubated 1 h with the
P3587 antibody followed by a 30 min-incubation with 10 nm-gold
particles-protein A (Utrecht University, Utrecht, The Netherlands).
2.8. Trypsin digestion
Onehundredmicrogramsofmitochondria, preparedasdescribed
above,were resuspended inmitochondrial isolation buffer and trea-
ted with increasing amount of trypsin (up to 100 lg/ml) for 20 min
on ice. The reaction was stopped by addition of protease inhibitors.
Mitochondria were isolated by centrifugation at 15 000g for
20 min and the mitochondrial proteins were then separated by
SDS–PAGE and subjected to Western immunoblotting.
2.9. Myocardial ischemia–reperfusion
Micewere subjected to coronary ligature for 1 h to producemyo-
cardial infarction, and then to reperfusion [10]. Themicewere killed
2 weeks later. Control mice were subjected to a similar operation
without tightening the coronary ligature. Ischemic and control left
ventricular samples were then frozen in liquid nitrogen, blended in
a potter, resuspended in Laemmli buffer and boiled for 5 min. An
equal amount of proteins was loaded on SDS–PAGE and subjected
to Western immunoblotting. Scanned radiographs were quantiﬁed
with ImageJ (National Institutes of Health, Bethesda, MD).
3. Results and discussion
3.1. Fem1a expression proﬁle in mouse organs and in differentiating
mouse C2C12 cells
In order to determine the expression proﬁle and the cellular
localization of mouse Fem1a and its human ortholog FEM1A, we
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bacterially-expressed FEM1A. In order to assess the speciﬁcity of
the P3587 antibody, we performed Western blot analyses on pro-
tein extracts from bacteria expressing human histidine-tagged
FEM1A. An anti-histidine antibody (Fig. 1A) as well as the P3587
antibody (Fig. 1B) detected a major immunoreactive band around
80 kDa. Knowing that a molecular weight of 76 kDa is predicted
for human FEM1A coupled to a 8-histidine tag, these experiments
show the speciﬁcity of the P3587 antibody. Lower immunoreactive
bands might reﬂect FEM1A degradation products.
Western blot analysis of Fem1a expression in mouse tissues
using the P3587 antibody revealed a single major immunoreactive
band around 90 kDa (Fig. 1C). Fainter bands were also detected in
brain, heart and liver; the signiﬁcance of these bands is unknown
and might be related to the presence of various Fem1a isoforms
with tissue-speciﬁc expression. No signal was detected under the
same conditions using the pre-immune serum (data not shown).
The Fem1a expression proﬁle showed that the protein is ubiqui-Fig. 1. Fem1a expression in mouse tissues and C2C12 cells. Bacteria were
transformed with the pQE-TriSystem vector encoding human FEM1A coupled to a
8-histidine tag. Western blot analysis of protein extracts from non-treated bacteria
(T0) or IPTG-treated bacteria for 1 h (T1) or 2 h (T2), using an anti-histidine
antibody (A) and the P3587 antibody raised against FEM1A (B). Western immuno-
blot analysis of mouse Fem1a using the P3587 antibody: (C) in mouse tissues such
as brain, uterus, skeletal muscle, heart, lung and liver (Br, Ut, Sk, He, Lu, Li); (D) in
cell extracts from C2C12 cells grown in proliferation medium (d0) or placed in
differentiation-promoting conditions for 2 days (d2), 4 days (d4) and 7 days (d7).
(E) Western immunoblot analysis of Fem1a in C2C12 cells grown in proliferation
medium (d0) or in differentiation-promoting conditions for 2 days (d2) and 6 days
(d6), after treatment with increasing amount of lambda phosphatase (0–1800
units). Positions of the phosphorylated Fem1a and of the dephosphorylated Fem1a
bands are indicated.tously expressed in the various organs tested, with a predominance
in brain, cardiac muscle and liver. This protein expression pattern
is slightly different from the mouse Fem1a gene expression pattern
described previously, showing an ubiquitous expression with a
predominance in cardiac and skeletal muscle [3]. The increased
Fem1a expression in brain, heart and liver, might reﬂect a speciﬁc
expression in organs enriched in mitochondria, even though this
pattern is not exactly similar to the expression pattern of Tom40,
a speciﬁc marker of mitochondria (Fig. 1C). We have also deter-
mined the protein expression levels of Fem1a during the differen-
tiation process of mouse C2C12 cells. The P3587 antibody
recognized a single band at 90 kDa in C2C12 cell lysates, reﬂecting
the speciﬁcity of the antibody. Furthermore, while Fem1a is ex-
pressed in C2C12 myoblasts, we observed a progressive increase
in the expression of the protein, concomitant to the formation of
C2C12 myotubes (Fig. 1D; data not shown). This result is in total
accordance with the Fem1a gene expression pattern that has been
previously described during the C2C12 differentiation process [2],
suggesting that Fem1a could play an important role in myogenesis.
In order to evaluate a possible post-translational phosphoryla-
tion of Fem1a, that could be responsible for the discrepancy be-
tween the observed Fem1a molecular weight ant its predicted
value, we subjected cell lysates from C2C12 myoblasts and myotu-
bes to a lambda phosphatase treatment. Western blot analysis
using the P3587 antibody revealed that phosphatase treatment in-
duced a dose-dependent generation of several immunoreactive
bands between 70 kDa and 80 kDa (Fig. 1E). Therefore, these data
suggest that Fem1a is highly phosphorylated in C2C12 myoblasts
and myotubes, and that dephosphorylated Fem1a has an apparent
molecular mass of 70 kDa, in accordance with its predicted molec-
ular mass of 72 kDa.3.2. Fem1a is a mitochondrial protein
The speciﬁcity of the P3587 antibody, demonstrated byWestern
blot on C2C12 cell lysates, was used to determine the subcellular
localization of Fem1a in C2C12 myoblasts and myotubes. Using a
mock-depleted P3587 antibody, indirect immunoﬂuorescence
showed a strong mitochondrial-like signal in C2C12 myoblasts,
while no signal was detected using the FEM1A-depleted P3587
antibody (Fig. 2a and b). Furthermore, no speciﬁc signal was de-
tected using the P3587 preimmune serum (Fig. 2c). In order to
demonstrate the mitochondrial localization of Fem1a, we per-
formed double-label indirect immunoﬂuorescence on C2C12 myo-
blasts using the P3587 antibody and a monoclonal antibody
directed against cytochrome c, a well-characterized component
of mitochondria. As can be seen in Fig. 2d–f, Fem1a colocalized
with the mitochondria-speciﬁc marker, suggesting that Fem1a is
a mitochondrial protein. A more diffuse staining was observed in
myotubes, overlapping the cytochrome c staining (Fig. 2g–i). Be-
cause it has been shown that FEM1A mRNA is downregulated in
various human rhabdomyosarcoma (RMS) cell lines [2], we
decided to determine the cellular localization of FEM1A in the
embryonic RMS cell line RD and in the alveolar RMS cell line
Rh28. Double-label indirect immunoﬂuorescence showed that
FEM1A colocalized with cytochrome c in the mitochondria of these
RMS cells (Fig. 2j–o). The mitochondrial localization of FEM1A was
also conﬁrmed using human HeLa cells (Fig. 2p–r). Finally, we per-
formed indirect immunoﬂuorescence microscopy on longitudinal
sections of tibialis anterior muscle from adult mice. The P3587
staining revealed regular rows of staining running across the skel-
etal muscle ﬁbers (Fig. 2s). Moreover, double-label immunoﬂuo-
rescence using an anti-a-actinin 2 antibody, a marker of skeletal
muscle Z-discs, revealed that the Fem1a staining is found at the
I-band level, on both sides of the Z-discs (Fig. 2s–u), an expression
Fig. 2. Cellular localization of mouse Fem1a and human FEM1A. Indirect immu-
noﬂuorescence was performed on mouse C2C12 myoblasts using the mock-
depleted P3587 antibody (a), the FEM1A-depleted P3587 antibody (b), or the
P3587 preimmune serum (c). Double-label indirect immunoﬂuorescence using the
P3587 antibody (P3587) and an anti-cytochrome c antibody (CytC) was performed
on C2C12 myoblasts (d–f), C2C12 myotubes (g–i), the human RMS cell line RD (j–l),
the human RMS cell line Rh28 (m–o), and human HeLa cells (p–r). Double-label
indirect immunoﬂuorescence was also performed using the P3587 antibody
(P3587) and an anti-a-actinin 2 antibody (Act2) on mouse skeletal muscle sections
(s–u).
Fig. 3. Fem1a is localized within mitochondria. (A) Cell fractionation was
performed on C2C12 myoblasts. The cytosolic marker tubulin, the mitochondrial
marker COX IV, and Fem1a were detected by Western immunoblotting in the total
cell lysate (Lysate), the cytosolic fraction (Cyto) and the mitochondria extract
(Mito). (B) Immunogold electron microscopy was realized on C2C12 myoblasts
using the P3587 antibody and a gold-conjugated secondary antibody. The 2 images
show mitochondria labeled with gold particles. (C) Puriﬁed mitochondria were
subjected to limited proteolysis with increasing concentration of trypsin from 40 to
100 lg/ml. After treatment, the mitochondrial outer membrane protein Tom40, as
well as Fem1a, are detected in the mitochondrial extract by Western immunoblot-
ting. (D) Helical wheel presentation of the N-terminal a helix of Fem1a, from
amino-acid 1 to 12. Hydrophobic residues are indicated in blue, while the
hydrophilic amino-acids are in red and the charged residues (+ or ) in black.
The ﬁrst methionine (amino-acid 1), at the top of the helical wheel, is considered as
a positively charged residue. (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)
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scribed in skeletal muscles [11].
In order to conﬁrm the mitochondrial localization of Fem1a that
we have observed using immunoﬂuorescence microscopy, we sub-
jected C2C12 myoblasts to cell fractionation. The purity of the
cytosolic and mitochondrial fractions was assessed using antibod-
ies raised against tubulin and COX IV. As seen in Fig. 3A, tubulin is
exclusively expressed in the cytosolic fraction, while the mitochon-
drial protein COX IV is enriched in the mitochondrial extract. Useof the P3587 antibody revealed that Fem1a is speciﬁcally detected
in the mitochondrial fraction, conﬁrming its mitochondrial locali-
Fig. 4. Up-regulation of Fem1a expression in ischemic hearts. (A) Cell fractionation
was performed on cardiac muscle cells. The cytosolic marker tubulin, the
mitochondrial marker VDAC, and Fem1a were detected by Western immunoblot-
ting in the total cell lysate (Lysate), the cytosolic fraction (Cyto) and the
mitochondria extract (Mito). (B) Fem1a expression levels in heart extracts were
detected by Western immunoblotting using the P3587 antibody: from 3 mice
subjected to myocardial ischemia–reperfusion (Myocardial infarction) and from 3
sham-treated mice (Sham). Expression levels of the mitochondrial maker VDAC
serve as an internal control for gel loading. (C) Graph representing the densito-
metric analysis of the Fem1a bands detected by Western immunoblotting in (B)
normalized against the VDAC bands. The data are expressed as the relative
expression of Fem1a in sham-treated hearts (Sham) and in ischemic hearts
(Myocardial infarction). Results are the mean ± S.E.M of three independent exper-
iments. Asterisk indicates statistical signiﬁcance at P < 0.02 according to the
unpaired Student’s t-test.
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localization of Fem1a, we performed immunogold electron micros-
copy on C2C12 myoblasts using the P3587 antibody. Even though a
relatively low amount of gold particles was detected, they were al-
most exclusively located in the inner part of the mitochondria
(Fig. 3B), while a control experiment using the secondary-labeled
antibody alone showed no non-speciﬁc staining within mitochon-
dria (data not shown). To further determine the precise mitochon-
drial localization of Fem1a, we subjected puriﬁed mitochondria to
limited trypsinization. This treatment is routinely used for the deg-
radation of cytosolic proteins bound to the outer mitochondrial
membrane or integral proteins of the outer membrane. Tom40,
an intrinsic protein of the outer mitochondrial membrane, was de-
graded by trypsin, while under the same conditions Fem1a was
protected from digestion (Fig. 3C), suggesting that Fem1a is neither
an extrinsic protein nor an intrinsic protein of the outer mitochon-
drial membrane. Altogether, these results show that Fem1a is an
internal mitochondrial protein. Furthermore, the mitochondrial
localization of Fem1a as well as the fact that the protein is nucle-
arly encoded led us to search for a mitochondrial targeting se-
quence within the protein. Because N-terminal amphipathic a
helices are common mitochondrial-targeting signals, we used the
PSIPRED algorithm [12] to predict the secondary structure of
Fem1a from its primary sequence. The program predicted the pres-
ence of a N-terminal a helix from amino-acid 5–12 (data not
shown). So, in order to determine whether this predicted a helix
could correspond to an amphipathic a helix, an helical wheel pre-
sentation of the 12 N-terminal residues is shown in Fig. 3D. Inter-
estingly, hydrophobic residues lie on one face of the helix while the
opposite face contains mostly hydrophilic and positively charged
amino-acids. This predicted N-terminal amphipathic a helix could
therefore correspond to a putative mitochondrial targeting signal
for Fem1a.
FEM1A has been proposed as a novel candidate gene for PCOS
[4,5], a common endocrine and metabolic disorder for which an
impaired expression of nuclear-encoded genes involved in mito-
chondrial oxidative metabolism has been observed in skeletal
muscles of patients [13]. Therefore, the demonstration that Fem1a
is a mitochondrial protein might open new horizons in the under-
standing and in the treatment of PCOS.
3.3. Increased Fem1a expression in ischemic hearts
It has been recently shown that Fem1a, also named EP4 recep-
tor-associated protein (EPRAP), interacts directly with the cyto-
plasmic tail of the EP4 receptor for prostaglandin E2 (PGE2) in
human macrophages, where it participates in anti-inﬂammatory
signaling [14]. Moreover, it has been demonstrated that mitochon-
dria express prostaglandin receptors and more speciﬁcally the EP4
receptor [15]. Furthermore, while PGE2 increases signiﬁcantly in
the heart during ischemia [16,17], PGE2 via the EP4 receptor has
a protective effect on hearts subjected to ischemia–reperfusion in-
jury [18]. We therefore decided to determine the expression levels
of Fem1a in mouse hearts after myocardial infarction. Preliminary
to these experiments, we decided to conﬁrm the mitochondrial
localization of Fem1a in cardiac muscle cells. Cell fractionation
was performed on cell extracts from mouse hearts, and expression
of the cytosolic marker tubulin, the mitochondria-speciﬁc protein
VDAC, and Fem1a were detected by Western immunoblotting. As
seen in Fig. 4A, Fem1a is exclusively detected in the mitochondrial
extract conﬁrming its mitochondrial localization in cardiac muscle
cells. To determine Fem1a expression levels in hearts after myocar-
dial infarction, mice were thus subjected to cardiac ischemia for
1 h followed by 15 days of reperfusion, while a sham operation
was used as a control condition. Fem1a expression levels, normal-
ized against the expression levels of the mitochondrial channelVDAC, were determined in the hearts of 3 myocardial-infarcted
mice and 3 sham-treated mice by Western immunoblotting. Wes-
tern immunoblots are shown in Fig. 4B, while densitometric anal-
ysis of the bands corresponding to Fem1a expression, normalized
against the VDAC bands, are represented in Fig. 4C. These results
show that Fem1a expression is signiﬁcantly increased by 86% in
hearts subjected to ischemia–reperfusion, suggesting that Fem1a
expression in heart is up-regulated upon myocardial infarction.
Fem1a up-regulation could be therefore a reaction to damage in or-
der to repair the heart muscle and/or may be part of the PGE2/EP4
receptor signaling pathway occurring after myocardial infarction.Acknowledgements
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